Literature DB >> 24165951

Gynaecological cancer: vintafolide--targeting the folate receptor with a cytotoxic offers hope.

Mina Razzak.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24165951     DOI: 10.1038/nrclinonc.2013.201

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Authors:  R Wendel Naumann; Robert L Coleman; Robert A Burger; Edward A Sausville; Elzbieta Kutarska; Sharad A Ghamande; Nashat Y Gabrail; Stephen E Depasquale; Elzbieta Nowara; Lucy Gilbert; Robert H Gersh; Michael G Teneriello; Wael A Harb; Panagiotis A Konstantinopoulos; Richard T Penson; James T Symanowski; Chandra D Lovejoy; Christopher P Leamon; David E Morgenstern; Richard A Messmann
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.